Biovista | Drug Positioning and Prioritization - Biovista Awarded $0.5M to Participate in EC’s Personalized Medicine Initiative

Article in GEN on Biovista’s participation in the Eurpean “p-medicine” project.

Drug repositioning specialist Biovista’s European affiliate has been awarded a $0.5 million grant to fund its participation in the European Commission’s €13.3 million (roughly $19.7 million), four-year p-medicine project focused on developing new tools and virtual physiological human (VPH) models to speed the development of personalized medicine. Biovista’s involvement in the 7^th Framework program will hinge on use of its Clinical Outcome Search Space (COSS) platform and profiling capabilities to identify therapeutics suitable for patients based on their pathophysiological characteristics.

…